(Q84192896)

English

Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer

scientific article published on 25 May 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21611734%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21611734%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

colorectal cancer

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

3

object named as

Narikazu Boku

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21611734%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

Taroh Satoh

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21611734%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Kensei Yamaguchi

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21611734%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Wataru Okamoto

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21611734%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Tomotaka Shimamura

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21611734%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Kentaro Yamazaki

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21611734%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Xiaojin Shi

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21611734%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Hideyuki Mishima

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21611734%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

publication date

25 May 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21611734%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21611734%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

30

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21611734%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21611734%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1511-1518

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21611734%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21611734

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/21611734

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/21611734

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of cediranib in combination with oxaliplatin and infusional 5-Fluorouracil in patients with advanced colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21611734

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21611734

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer In

1 reference

https://pubmed.ncbi.nlm.nih.gov/21611734

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/21611734

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety

1 reference

https://pubmed.ncbi.nlm.nih.gov/21611734

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours

1 reference

https://pubmed.ncbi.nlm.nih.gov/21611734

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21611734

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study

1 reference

https://pubmed.ncbi.nlm.nih.gov/21611734

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21611734

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Systemic therapy for colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21611734

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21611734

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21611734

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q84192896&oldid=2221546540"